A research team from Toulouse has just elucidated the mechanisms behind the differences in iron absorption between men and women. The team used mice to demonstrate how the action of testosterone can be “countered” with a drug already used in the treatment of some bronchial cancers. The results are published this month in the Hepatology review.
The regulation of the iron metabolism differs between men and women. As a consequence, chronic liver diseases associated with a reduced hepcidin production capacity – a hormone that inhibits iron absorption by the duodenum – are often more severe in men than in women.
This is the case for hepatitis C, alcoholic liver disease and hereditary hemochromatosis.
With a view to better understanding the underlying mechanisms of this sexual dimorphism, Marie-Paule Roth and her co-workers at the Centre for Physiopathology in Purpan (Mixed Inserm/CNRS/Université Paul Sabatier Research Unit, Toulouse) have taken advantage of the major differences in hepcidin expression and iron overload observed in male and female mice with iron metabolism disorders.
The researchers showed that testosterone robustly represses hepcidin transcription in these mice since it activates the growth factor receivers in the liver (EGF). Yet, when these EGF receivers are inhibited in male mice by a drug used in the treatment of some bronchial cancers, testosterone-induced repression ceases. Hepcidin production is then significantly increased. Castrating male mice leads to an increase in hepcidin production, as well as a very strong reduction in iron overload in the heart and pancreas of these mice.
To conclude, Marie-Paule Rothe and her team emphasise: “These results indicate that the testosterone-induced repression of hepcidin may have clinical repercussions for patients who, for different reasons, are only capable of producing hepcidin in limited quantities. Inhibiting the activation of EGF receivers in these patients could help them to produce more hepcidin, thus limiting iron overload that worsens the prognosis of chronic liver disease” they explain.
(Français) Matteo Serino, chargé de recherche Inserm à l’Institut de recherche en santé digestive (IRSD, une unité mixte de recherche Inserm/Université Toulouse III- Paul Sabatier/Ecole nationale vétérinaire de Toulouse/Inra), et ses collaborateurs, montrent que l’altération du microbiote intestinal, qu’elle soit d’origine nutritionnelle ...
What if immune system efficacy against cancerous cells could be reinforced by a diet in which calories are not reduced but nutrients are precisely determined? This what Inserm researchers from Université Côte d’Azur, through a study of the effects of restrictive diets ...
Chloé Latour1,2,3, Léon Kautz4,5, Céline Besson-Fournier1,2,3, Marie-Laure Island6,7,François Canonne-Hergaux1,2,3, Olivier Loréal6,7, Tomas Ganz4,5, Hélène Coppin$1,2,3, Marie-Paule Roth$1,2,3
1Inserm, U1043, Toulouse, F-31300, France
2CNRS, U5282, Toulouse, F-31300, France
3Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France
4Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, USA
5Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
6Inserm, UMR991, Rennes, F-35000, France
7Université de Rennes 1, Rennes, F-35033, France
Hepatology 2013 Aug 1